HHS Allows 503A Pharmacies to Compound Six Peptides, With Conditions. Here's What That Means
HHS Allows 503A Pharmacies to Compound Six Peptides, With Conditions. Here’s What That Means.
For current status, see The Road to Legal Peptide Compounding: Where BPC-157 and Others Stand Today
The short version: On October 28, 2026, the Department of Health and Human Services (HHS) announced a policy saying it won’t take enforcement action against state-licensed 503A pharmacies and physicians that compound six peptides, as long as they meet specific conditions. It’s temporary, it isn’t FDA approval, and it doesn’t apply to 503B outsourcing facilities. HHS is taking public comments, so the details could change. The conditions are strict, and they decide whether a product is compliant.
What happened
HHS announced an “Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances.” The notice was filed with the Federal Register on October 28, 2026, and is scheduled for official publication on October 30, 2026. It follows the July 2026 FDA advisory committee vote recommending these peptides for the 503A bulks list. The Federal Register notice calls it a draft, and public comments are open for two weeks after publication under Docket No. HHS-OASH-2026-0496.
Enforcement discretion means the government is choosing not to act against compounding that meets the policy’s conditions. The policy stays in place until FDA addresses each peptide in a final rule.
In practice, 503A pharmacies that meet every condition can compound and dispense these peptides by prescription without federal enforcement action.
HHS says the policy is meant to give patients a more controlled alternative to “research use only” peptides from foreign manufacturers. Our position is simple: we’re on the side of legal compounding, meaning drug products made within the law for patients whose treating clinician decides they need them.
Allowed isn’t the same as legal
This is the most important distinction in the policy. The law hasn’t changed.
These peptides still don’t meet the requirements of section 503A: they aren’t on the bulks list, they don’t have a USP monograph, and they aren’t part of an FDA-approved drug. HHS is choosing not to enforce those requirements, for now, against compounders that follow its conditions.
In plain terms, the government is choosing not to enforce the rules for now, and it can change its mind at any time. HHS says it may revisit the policy, in whole or in part, if a safety signal or product-quality issue comes up. That flexibility lets the government act quickly. If products are made poorly and patients are harmed, the policy could be narrowed or withdrawn for everyone, including the pharmacies that followed every condition.
State boards of pharmacy and medicine were never bound by the policy. They can act under state law at any time, and each state may choose to be stricter than the federal government.
For practices, that means the question isn’t just whether a pharmacy is allowed to make these peptides. It’s whether the pharmacy meets every condition, and can show you that it does.
A few terms, in plain English
a state-licensed pharmacy that compounds medications for individual patients with a prescription.
a facility registered with and inspected by FDA that makes larger batches, often supplied to clinics as office stock.
Bulk drug substance or raw material ingredient a compounder starts with.
a public quality standard that spells out how an ingredient must be tested and what results it must meet.
the test report that shows what’s in a specific lot of an ingredient.
how much active ingredient is actually in the product, compared with what the label says.
Which peptides, and which routes
The policy covers six peptides, and only in specific forms and routes. Emideltide (DSIP), which the advisory committee voted against, is not included.
| Peptide | Covered routes |
|---|---|
| BPC-157 (acetate) | Subcutaneous, intramuscular, oral, topical |
| TB-500 (acetate) | Subcutaneous, intramuscular |
| MOTS-c (acetate) | Subcutaneous, intramuscular |
| Epitalon (acetate) | Subcutaneous, intramuscular, in intermittent courses |
| Semax (free base) | Intranasal |
| KPV (acetate) | Topical, oral |
A product outside these routes falls outside the policy. For example, injectable Semax and injectable KPV are not covered.
No USP monograph means no shared quality standard
None of these six peptides has a USP monograph. That’s one of the most important things to understand about them.
For most ingredients a compounder uses, the USP monograph sets the rules everyone follows: which tests to run, how to run them, and what results the ingredient must meet for identity, purity and strength. Two pharmacies using the same monograph ingredient are working to the same public standard.
Without a monograph, there is no shared standard. Each supplier and each compounder sets its own specifications: which tests to run, what counts as a pass, how much impurity is acceptable. Two products with the same name on the label can be made to very different standards, and from the outside they look identical.
The policy tries to fill that gap. It lists testing that the ingredient’s certificate of analysis must cover. But that applies to the raw ingredient. How the finished product is made and tested still varies from pharmacy to pharmacy. That raises questions every practice should ask:
- Who made the peptide API, and how was it tested?
- What specifications does the pharmacy hold its finished product to?
- Does the pharmacy test each finished lot, and for what?
- Can it show you the results?
The peptides also differ in complexity. The policy requires extra testing for peptides with 8 or more amino acids, because longer chains are harder to make cleanly and to characterize. BPC-157 (15 amino acids) and MOTS-c (16) sit at the more complex end. KPV (3) and Epitalon (4) are simpler.
Chain length in amino acids, for the four peptides named above
The conditions
A compounded peptide is covered only if it meets all of these:
- Single ingredient. One covered peptide per product. Combinations, such as BPC-157 with TB-500, are not covered.
- A registered original manufacturer. The raw peptide must come from an FDA-registered, CGMP-compliant manufacturer, and that manufacturer’s location must appear on the certificate of analysis. A distributor’s registration doesn’t substitute. If the ingredient passes through a repacker or reseller, that company must validate the manufacturer and its certificate.
- A full Certificate of Analysis. The CoA must identify and characterize the peptide, with testing for identity, purity, potency and contaminants such as endotoxins, heavy metals, microbes and impurities. It must name the original manufacturer with its FDA registration (FEI) number and address, and state the grade as “Intended for human drug compounding.”
- Oral products need proof of absorption. Peptides are hard to absorb by mouth, so a compounder making an oral form must keep documentation that the specific formulation is adequately absorbed in people.
- A patient-specific prescription and sanitary conditions. Standard 503A rules still apply, so these are compounded for individual patients, not as office stock, and never under insanitary conditions.
- Labeling. The label must say “This is a compounded drug product. Not for resale.” The labeling given to the patient should explain how to report side effects and quality problems.
- Reporting. Compounders must report their products, serious adverse events and quality problems to FDA and to the states involved.
- Delivery devices. Vials are fine. If a device is packaged with the product or holds it, such as a prefilled syringe, it must be an FDA 510(k)-cleared syringe. Pens, auto-injectors and other more complex devices aren’t covered.
Where compounders are most likely to fall short
Two conditions will be the hardest for many pharmacies to meet:
- The Certificate of Analysis. It must meet the testing standard in the policy’s Appendix B and name the original manufacturer, its FEI number and the grade “Intended for human drug compounding.” That testing standard is more demanding than what many peptide suppliers have provided in the past, so ingredients bought before the policy may not qualify.
- Single ingredient, in a covered route. Blends such as BPC-157 with TB-500 are popular, but they aren’t covered. Neither are routes outside the policy, such as injectable Semax or injectable KPV. A product can come from a licensed pharmacy and still fall outside the policy.
If a pharmacy can’t show you both, its product isn’t covered by the policy.
What it doesn’t do
- It isn’t FDA approval. Compounded drugs are not FDA approved, and FDA doesn’t review them for safety, effectiveness or quality before they reach patients.
- It doesn’t cover 503B outsourcing facilities. The policy is written for 503A compounding. 503B office stock of these peptides is still not allowed.
- It doesn’t create a quality standard for the finished product. The policy sets testing for the raw ingredient, but there is still no USP monograph for any of these peptides.
- It doesn’t override state law. State boards of pharmacy and medicine may set their own rules, and some may not follow the federal approach.
- It doesn’t make “research use only” products legal. Products sold as lab chemicals are still not made for use in people.
- It isn’t permanent. HHS can change or withdraw it, and a final rule could include or exclude each peptide.
What this means for your practice
The policy opens a lawful path through 503A pharmacies, but only for products that meet every condition. With no USP monograph behind these peptides, the pharmacy you choose matters more than usual. Before you order, ask:
-
“Is this a single-ingredient product, in a route the policy covers?”
Red flag: blends, or routes outside the policy, such as injectable Semax.
-
“Who is the original manufacturer of the peptide API, and what is its FDA registration (FEI) number?”
Check: the manufacturer’s name and location appear on the certificate of analysis, and the registration matches in FDA’s database.
Red flag: only a distributor’s name, or “that’s proprietary.”
-
“Send me the certificate of analysis for the raw ingredient.”
Check: it names the original manufacturer with its FEI number, and the grade reads “Intended for human drug compounding.”
Red flag: a generic “sample” certificate, or a grade like “research use only.”
-
“Do you test potency on every finished lot, and can you send me the results for the lot you’ll ship, along with sterility and endotoxin?”
Why it matters: sterility and endotoxin results tell you the product is clean. Potency tells you the dose is what the label says. Federal rules don’t generally require 503A pharmacies to potency-test every lot, so many don’t. A pharmacy that does, and can show you the results for your lot, is giving you real evidence it makes what it says it makes.
Check: the lot numbers match your order, and the potency result matches the strength on the label.
Red flag: “we test periodically,” or no potency testing at all.
-
“When was this lot compounded, and was it made under the policy’s conditions?”
The policy was announced October 28, 2026. Ask how earlier lots were made.
-
“Are you licensed to ship to my state?”
Check: the pharmacy holds a license, or a nonresident license, in your state.
Federal enforcement discretion doesn’t bind state boards of pharmacy or medicine. If you’re unsure whether your state allows these products, ask your state board.
Remember that 503A products are compounded for individual patients. You can’t keep them as office stock.
If you choose to use these peptides, potency testing on every lot is one of the clearest signs a pharmacy can back up its label.
For patients
If you’re receiving or considering one of these peptides, it can now be compounded by a licensed 503A pharmacy, with a prescription, under strict conditions. There’s no official public standard for how these peptides must be made, so two products with the same name can be quite different. It’s reasonable to ask your provider which pharmacy makes yours, and whether that pharmacy tests each batch to confirm it contains what the label says. Products sold online as “research use only” still aren’t made for use in people. Whether any treatment is right for you is a conversation for you and your provider.
Where McGuff fits
McGuff Outsourcing Solutions (MOS) is an FDA-registered 503B outsourcing facility. This policy covers 503A compounding only, so it doesn’t change what MOS can make, and we don’t compound these peptides. For a 503B, the path runs through the 503B bulks list, which is based in part on whether there’s a clinical need for outsourcing facilities to make a substance. If a lawful 503B path opens, we’ll evaluate these peptides the same way we evaluate every product.
Why we’re covering this
We don’t make claims about how well these peptides work. Whether a treatment is right for a patient is a decision for that patient and their clinician.
What we can speak to is how a drug is made. FDA and HHS decide what can legally be compounded. Clinicians decide what’s right for each patient. Our job is everything in between: designing quality into the process from the start, sourcing raw materials from FDA-registered manufacturers, and testing every batch before it’s released, so the product is what the label says it is.
This policy puts those same questions front and center: who made the ingredient, how it was tested, and whether the product matches its label. Without a USP monograph, those questions matter even more. They’re the questions that matter for any compounded drug, whoever makes it.
Current statusThe Road to Legal Peptide Compounding: Where BPC-157 and Others Stand TodaySources
McGuff Outsourcing Solutions is a DBA of McGuff Pharmaceuticals, Inc., an FDA-registered 503B outsourcing facility. Compounded drugs are not FDA approved. FDA approval applies to drugs reviewed through a New Drug Application (NDA) or Abbreviated New Drug Application (ANDA). Compounded drugs are regulated under a separate framework: 503A pharmacies are overseen primarily by state boards of pharmacy, and 503B outsourcing facilities register with FDA, are inspected by FDA and must follow CGMP requirements. FDA does not review compounded drugs for safety, effectiveness or quality before they reach patients. This article is for educational purposes only and is not medical or legal advice. Patients should talk with their healthcare provider about any treatment.
